FDA Approves First Drug for Postpartum Depression

The FDA has approved the first drug ever specifically for postpartum depression, Zulresso (brexanolone).

Zulresso is given intravenously. Because of concerns such as sudden loss of consciousness and extreme sedation after administration, the approval of the drug was given with a Risk Evaluation and Mitigation Strategy (REMS). This means that Zulresso will only be available through certified healthcare facilities where a patient can be monitored during the infusion, which takes 60 hours (2.5 days).

Zulresso should be available to women by the end of June.

The most common side effects reported by patients on Zulresso in clinical trials were sleepiness, dry mouth, loss of consciousness and flushing. If a patient’s depression becomes worse or they experience suicidal thoughts and behaviors while on Zulresso, healthcare providers should consider discontinuing the drug.

Zulresso’s efficacy was demonstrated in two double-blind, placebo-controlled trials. In both studies, Zulresso was superior to placebo in terms of reducing depressive symptoms at the end of the infusion and 30 days later.

The drug was granted both Priority Review and Breakthrough Therapy designations by the FDA.

The former is for investigational drugs that may offer a significant improvement in the treatment of a condition; the latter is given to drugs that address an unmet medical need.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Drug Overdoses Misreported as Cardiac Arrests, Study Shows

Drug Overdoses Misreported as Cardiac Arrests, Study Shows

You’ve heard about misreported causes of death a lot recently. For example, the debate rages on about the actual number of people who have died of COVID-19 because the way “cause of death” differs from state to state and even hospital to hospital. The problems that an untrustworthy count causes…

Inactive Ingredients, Heparin for COVID-19, and Dangerous Hand Sanitizer

Inactive Ingredients, Heparin for COVID-19, and Dangerous Hand Sanitizer

Happy Tuesday, everyone. Another week is in the books, and we’re pleased to have some good news to report. But first the bad news: It turns out that certain inactive ingredients in drugs may have an effect on you, and the FDA added to their list of subpar and potentially…

  • Advertisement